Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adaptive Study of the Safety, Tolerability & Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell®) in Patients With Advanced Cancers Refractory to Current Treatment or Have Indolent Disease for Which Immunotherapy May be Beneficial

NCT02459067 is registered in ClinicalTrials.gov with TC Biopharm as lead sponsor.

NCT NCT02459067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02459067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adaptive Study of the Safety, Tolerability & Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell®) in Patients With Advanced Cancers Refractory to Current Treatment or Have Indolent Disease for Which Immunotherapy May be Beneficial
Lead sponsor
TC Biopharm
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2015
Completion date
November 27, 2018
Enrollment
8 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma, non-small cell lung cancer, renal cell cancer